Open Nav

Reglagene Holding, Inc.

Subscribe the current round, make contacts for a future round, and identify alliance partners

  • Date:Thursday, October 18
  • Time:11:00 AM - 11:15 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Reglagene is a platform therapeutics discovery and development company that leverages DNA quadruplexes as master control elements of gene expression. Our focus is oncology as the expression of many intractable oncogene targets is under quadruplex control. Reglagene's lead program is the down-regulation of telomerase reverse transcriptase (hTERT). Reglagene possesses proprietary and drug-like small molecules that block hTERT expression. Restricting hTERT expression accesses non-canonical telomerase biology that results in oxidative DNA damage and cancer cell apoptosis in a matter of days, a therapeutically viable result distinct from classic telomerase enzyme inhibition approaches. In vivo proof of concept has been demonstrated. Reglagene will earn revenue through partnering its assets after achievement of sufficient proof of concept and through research alliances. Reglagene is currently raising a $2M seed round. $1.5M remains unsubscribed.
  • Company Website:www.reglagene.com
  • Company HQ City:Tucson
  • Company HQ Country:United States
  • Company HQ State:Arizona                        
  • CEO/Top Company Official:Richard Austin
  • Year Founded:2016
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Down-regulators of telomerase reverse transcriptase (hTERT) for applications in oncology
  • Development Phase of Primary Product:Discovery
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:Reglagene is raising its first funding round. We are seeking a modest raise at a modest valuation because, as a Tucson company, we felt it important to first win the backing of Arizona investors. Investment in early-stage therapeutics opportunities in Arizona is a hard sell. But now that we have been successful at home, we are taking our message to the dedicated biotech investment community and recently attended June's BIO Conference in Boston. We found that BIO meeting to be the most productive partnering forum that we have attended and want to increase Reglagene's exposure via presentation at BIO's Investor Conference. We have additional validation via selection (in administrative review) for a $300K National Cancer Institute STTR Phase I award. Reglagene is an Innovation Excellence winner of the Freedom from Cancer Startup Challenge. We are also engaged with several pharmaceutical companies discussing early stage alliances.
  • Previous and Current Investors:Company founders and individual angel investors. Deal lead is Tucson's Desert Angels
  • Size of Last Investment Round:Currently raising a $2M seed round, $1.5M remains unsubscribed
  • Total Amount Raised to Date, In All Rounds:$546K
Back